Prescriber Scope of Practice for Narcolepsy in North Carolina

If you’re a psychiatrist or PMHNP considering treating narcolepsy patients remotely, you’ve probably wondered: Can I legally prescribe stimulants and other controlled substances via telehealth? The short answer in 2026 is yes — but with important caveats that vary by state.

Narcolepsy treatment typically requires Schedule II stimulants (methylphenidate, amphetamines), Schedule IV wakefulness agents (modafinil, armodafinil), or even Schedule III sodium oxybate. Under normal federal law (the Ryan Haight Act), prescribing any controlled substance via telemedicine requires at least one in-person exam. But thanks to COVID-era flexibilities extended through December 31, 2026, providers can currently initiate and manage these medications entirely via telehealth — as long as you navigate state-specific rules correctly.

Here’s what you need to know about prescribing narcolepsy medications remotely, the regulatory landscape, and how scope of practice differs for psychiatrists versus PMHNPs across key states.

Federal Law: The DEA’s Telehealth Extension (and What Comes Next)

The Ryan Haight Act (21 U.S.C. §829) normally requires an in-person medical evaluation before any controlled substance can be prescribed via the internet or telemedicine. This 2008 law was designed to curb illegal online pharmacies, but it also created a barrier for legitimate telehealth providers treating conditions like narcolepsy, ADHD, or chronic pain.

When COVID hit in March 2020, the DEA waived this requirement to prevent care disruptions. That waiver has been extended multiple times — most recently through the end of 2026 — giving providers a stable window to prescribe controlled narcolepsy medications via video visits without an initial in-person exam.

What this means for you now:

• You can evaluate a new narcolepsy patient via telehealth (video) and prescribe Schedule II–V medications if it’s medically appropriate
• Standard requirements still apply: valid DEA registration, state medical license where the patient is located, checking your state’s prescription drug monitoring program (PDMP), and e-prescribing
• You must document a thorough evaluation — history, mental status exam, rating scales (like the Epworth Sleepiness Scale), and coordinate diagnostic testing (polysomnography, Multiple Sleep Latency Test) as needed

What’s coming: The DEA has been drafting permanent telemedicine rules since 2022. Early proposals suggested requiring an in-person visit after an initial 30-day telehealth prescription for Schedule II drugs, but faced massive pushback (over 38,000 public comments). As of early 2026, no final rule has been published. The only finalized carve-outs so far are for buprenorphine in opioid use disorder and VA health system continuity of care.

Expect the eventual permanent rules to include some safeguards (possibly initial supply limits or follow-up requirements), but they’ll likely be more flexible than the original proposal given the strong advocacy from telehealth providers and patient groups. Until then, you’re operating under the 2026 extension — so get your systems in place now, but plan for potential changes in 2027.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State-by-State Reality: Where It Gets Complicated

Federal law sets the baseline, but states add their own layer of telehealth and controlled substance regulations. Some states defer entirely to federal rules; others impose stricter requirements that can make narcolepsy treatment via telehealth difficult or impossible.

Florida: The Outlier

Florida’s telehealth statute (Fla. Stat. §456.47) explicitly prohibits prescribing Schedule II or III controlled substances via telehealth — with four narrow exceptions: treating a psychiatric disorder, inpatient hospital care, hospice, or nursing home residents.

Here’s the problem: Narcolepsy is not a psychiatric disorder. It’s a neurological sleep condition. So even though modafinil (Schedule IV) can be prescribed via telehealth in Florida, you cannot legally prescribe Adderall, Ritalin, or other Schedule II stimulants to a narcolepsy patient remotely.

Workarounds for Florida providers:

• Start patients on modafinil or armodafinil (Schedule IV) via telehealth
• Require at least one in-person visit (or coordinate with a local provider) before prescribing Schedule II stimulants
• For PMHNPs: Florida also limits NPs to a 7-day supply of Schedule II drugs unless you’re a certified ‘psychiatric nurse’ treating mental illness — which again, narcolepsy doesn’t qualify for

Bottom line: Florida’s strict law makes purely virtual narcolepsy care challenging. You’ll need a hybrid model or local partnerships.

New York: Aligned with Federal Rules (For Now)

New York updated its regulations in May 2025 to formalize telehealth prescribing of controlled substances. The state generally requires an in-person exam before prescribing controlled drugs unless you meet one of several exceptions — including compliance with federal law (i.e., the current DEA waiver).

This means:

• While the DEA extension is in effect through 2026, you can prescribe narcolepsy medications via telehealth in New York without an in-person visit
• If/when federal rules tighten, New York’s requirement will automatically kick back in (you’d need an in-person exam or meet another exception, like covering for a provider who saw the patient in person)
• PMHNPs in New York have full practice authority after 3,600 hours of experience — you can diagnose and prescribe independently, including Schedule II drugs, as long as you’re compliant with state and federal law

Practical note: New York requires checking the I-STOP PDMP before every controlled substance prescription and mandates e-prescribing. Make sure your EHR integrates these workflows.

Texas: Physician Oversight Required for NPs

Texas allows telehealth establishment of a provider-patient relationship via live video — but APRNs and PAs cannot prescribe Schedule II drugs outside hospital or hospice settings. Period.

If you’re a PMHNP in Texas treating narcolepsy:

• You can prescribe modafinil (Schedule IV) under a physician delegation agreement
• You cannot prescribe Adderall or other Schedule II stimulants — a supervising physician must write those prescriptions
• Texas law also limits a physician to supervising 7 APRNs/PAs in outpatient settings, which can constrain scaling

For psychiatrists in Texas, there are no special state-level barriers beyond federal rules. But be aware: Texas law bans telehealth prescribing of controlled substances for chronic pain management (requiring in-person visits every 90 days) — this doesn’t affect narcolepsy, but it’s worth knowing if you’re treating comorbid conditions.

Technology requirement: Texas mandates two-way audio and video for any telehealth visit where you’re prescribing controlled substances. A phone call alone won’t cut it.

California: NP Independence Expands Access

California has been phasing in full practice authority for NPs under AB 890. As of 2023, experienced NPs (≥4,600 hours of supervised practice) can practice independently, including prescribing Schedule II–V medications after completing required pharmacology training.

For narcolepsy care:

• Psychiatrists have full authority with no unique state restrictions on telehealth prescribing
• PMHNPs with independent certification can diagnose and manage narcolepsy entirely via telehealth, including prescribing stimulants
• You must obtain a California furnishing number with Schedule II authority and a DEA registration
• California requires checking the CURES PDMP before prescribing Schedule II–IV drugs initially, then every 4 months

This makes California one of the most NP-friendly states for expanding virtual narcolepsy services, especially in underserved rural areas.

Pennsylvania and Illinois: Collaboration vs. Independence

Pennsylvania still requires physician collaboration for NPs (CRNPs). You can prescribe Schedule II–V drugs under a collaborative agreement, but there’s a 30-day supply limit on Schedule II prescriptions (refills require physician consultation). For ongoing narcolepsy management, you’ll need regular physician involvement.

Illinois grants full practice authority to NPs after 4,000 hours of collaboration + 250 hours of additional training. Once you achieve FPA status, you can prescribe independently — including Schedule II stimulants for narcolepsy. Illinois is part of the Interstate Medical Licensure Compact (for MDs) and recently joined the APRN Compact, which will streamline multi-state licensing once fully operational.

Both states defer to federal law on telehealth controlled substance prescribing and don’t impose additional in-person visit requirements beyond the DEA rules.

Psychiatrist vs. PMHNP Scope: What You Need to Know

Psychiatrists (MD/DO) have unrestricted authority to diagnose and treat narcolepsy in all 50 states, assuming proper licensure and DEA registration. The only limitations are state-specific telehealth rules (like Florida’s ban on remote Schedule II prescribing for non-psychiatric conditions).

PMHNPs face a patchwork of scope restrictions:

Bottom line: If you’re a PMHNP, your ability to manage narcolepsy patients remotely depends heavily on your state. In full practice states like California, New York, and Illinois, you can operate independently. In restricted states like Texas and Florida, you’ll need physician collaboration — which may mean bringing in an MD for Schedule II prescriptions.

The Economics: Why Telehealth Platforms Make Sense for Narcolepsy Care

Let’s talk about the business reality of building a narcolepsy practice.

DIY patient acquisition is expensive and slow:

• SEO takes 6–12 months of consistent investment before you see meaningful patient flow
• Google Ads for mental health keywords run $15–40+ per click, and most clicks don’t convert. A realistic cost per booked patient through PPC is $200–400+
• Directory listings (Psychology Today, Zocdoc) charge monthly fees AND you compete with hundreds of other providers on the same page
• When you factor in agency fees, ad spend testing, staff time to qualify leads, and no-show rates, total patient acquisition cost through DIY marketing often exceeds $200–500+ per patient

For specialized care like narcolepsy, the economics are even tougher:

• It’s a rare condition (affects ~1 in 2,000 people), so you’re fishing in a small pond
• Most patients don’t know they have narcolepsy — they just know they’re exhausted all the time
• Traditional directories aren’t optimized for sleep disorders, so reaching the right patients is hard
• You need diagnostic coordination (sleep studies), which adds friction to the patient journey

Platforms like Klarity Health remove this friction:

• No upfront marketing spend — you pay a standard listing fee per new patient lead, not a monthly subscription
• Pre-qualified patients already matched to your specialty and availability
• Built-in telehealth infrastructure (no separate platform costs, EHR integration, PDMP checks)
• Both insurance and cash-pay patient flow — you’re not limited to one payer model
• You control your schedule — only pay when you see patients, guaranteed ROI vs. gambling on marketing channels

Instead of spending $3,000–5,000/month on marketing with uncertain results, you pay only when a qualified patient books with you. For a specialized service like narcolepsy care, that predictability matters — especially when you’re navigating complex state regulations and building a multi-state practice.

Practical Steps: Building a Compliant Telehealth Narcolepsy Practice

1. Get licensed in your target states

• Psychiatrists: Consider joining the Interstate Medical Licensure Compact (IMLC) if your primary state is a member — it streamlines licensing across 40+ states (though California, New York, and Florida aren’t members)
• PMHNPs: Check if your state participates in the APRN Compact (Illinois joined in 2023; rollout is ongoing)

2. Obtain DEA registration and state-specific permits

• Single DEA number covers all states where you’re licensed, but you need a physical address in each state
• Some states require additional registration (e.g., New York’s Bureau of Narcotic Enforcement, Illinois mid-level controlled substance license)

3. Integrate PDMP checks into your workflow

• Every state requires checking the prescription monitoring database before prescribing controlled substances
• Many EHRs now integrate PDMP lookups — make it a standard part of your intake process

4. Use e-prescribing for all controlled substances

• Federal law and most states now mandate electronic prescribing of Schedule II–V drugs
• Your e-prescribing system must meet DEA requirements (two-factor authentication, secure transmission)

5. Document thoroughly

• Even though you’re not seeing patients in person, your documentation should be as detailed as an in-person visit
• Include: chief complaint, comprehensive sleep history, review of systems, mental status exam, assessment of suicide/safety risk, rationale for controlled substance prescribing, risks/benefits discussed with patient, plan for diagnostic testing, follow-up schedule

6. Coordinate diagnostic testing

• Narcolepsy diagnosis often requires polysomnography and Multiple Sleep Latency Testing
• Establish referral relationships with sleep labs in your patients’ geographic areas
• Document how you’re confirming the diagnosis if you’re initiating treatment based on a prior provider’s work-up

7. Plan for regulatory changes

• Monitor DEA announcements closely as 2026 progresses
• If new rules require an in-person exam for initial Schedule II prescriptions, you’ll need a strategy — hybrid care model, local clinic partnerships, or limiting your practice to Schedule IV medications until an in-person visit occurs

8. Consider malpractice insurance and risk management

• Ensure your malpractice coverage includes telehealth and prescribing controlled substances across state lines
• Follow all risk management best practices: verify patient identity, obtain informed consent for telehealth, schedule frequent follow-ups initially (especially for stimulants), have an emergency plan

Why Narcolepsy Care via Telehealth Matters (and Why Klarity Can Help)

Narcolepsy is dramatically underdiagnosed and undertreated. The average time from symptom onset to diagnosis is 8–10 years. Most patients see multiple providers who misdiagnose them with depression, sleep apnea, or ‘laziness’ before someone finally orders the right tests.

Once diagnosed, patients face a new challenge: finding a provider willing to prescribe and manage controlled medications long-term. Many primary care docs are uncomfortable with Schedule II stimulants. Neurologists and sleep specialists are scarce, with wait times stretching months in many areas.

Telepsychiatry bridges this gap — if you can navigate the regulatory maze. Psychiatrists and PMHNPs already prescribe stimulants for ADHD; adding narcolepsy to your scope is a natural extension. The medications overlap (methylphenidate, amphetamines, modafinil), the prescribing workflows are similar, and you’re already comfortable with the risk management.

But here’s the catch: building a narcolepsy patient base through traditional marketing is slow and expensive. You’re targeting a rare condition, competing with established sleep centers, and investing heavily in SEO or ads with no guarantee of ROI.

Klarity Health solves this problem by connecting you with pre-qualified patients who are already seeking psychiatric or specialized care. Instead of spending months and thousands of dollars on marketing, you get matched with patients who need your expertise — and you only pay when they book with you. The platform handles scheduling, telehealth infrastructure, and patient acquisition, so you can focus on what you do best: providing great care.

Whether you’re a psychiatrist looking to expand into underserved markets or a PMHNP building an independent practice in a full-authority state, Klarity gives you the patient volume and operational support to make it work — without the financial risk of DIY marketing.

The Bottom Line

Yes, you can prescribe narcolepsy medications via telehealth in 2026 — but ‘can’ depends on where you’re licensed, what your credentials are, and whether you’re willing to navigate state-specific regulations.

• Federal law allows it through December 2026 under the DEA’s COVID-era waiver
• State laws vary dramatically: Florida effectively bans remote Schedule II prescribing for narcolepsy; New York, California, and Illinois allow it with proper licensing
• Psychiatrists have full authority in all states (subject to state telehealth rules); PMHNPs face scope restrictions in Texas, Florida, and Pennsylvania
• Building a profitable telehealth practice requires either massive upfront marketing investment OR partnering with a platform that handles patient acquisition for you

If you’re ready to expand your practice into narcolepsy care, now is the time — the regulatory window is open, patient demand is high, and platforms like Klarity can connect you with qualified patients without the marketing gamble.

Ready to join Klarity’s provider network? We handle patient acquisition, credentialing, and telehealth infrastructure so you can focus on delivering great care. Learn more at Klarity Health Providers or reach out to explore how we can help you build a thriving telehealth practice.

Frequently Asked Questions

Q: Do I need special training or certification to treat narcolepsy as a psychiatrist or PMHNP?
A: No special certification is required. However, you should be familiar with sleep disorder diagnostics and comfortable coordinating polysomnography/MSLT testing. Many providers pursue additional CME in sleep medicine, but it’s not legally mandated.

Q: Can I prescribe sodium oxybate (Xyrem) via telehealth?
A: Yes, under the current DEA waiver. However, sodium oxybate is a Schedule III drug with an FDA-mandated REMS program — you must be enrolled in the REMS registry to prescribe it, which involves additional training and certification. The REMS program also restricts which pharmacies can dispense it.

Q: What happens when the DEA waiver expires at the end of 2026?
A: The DEA will likely finalize permanent telemedicine rules sometime in 2026. Based on public feedback, those rules will probably be more flexible than the original 2023 proposal — but may still require an in-person exam for initial Schedule II prescriptions or impose supply limits. Monitor DEA announcements closely and be prepared to adjust your practice model.

Q: Can I prescribe across state lines if I have licenses in multiple states?
A: Yes, as long as you’re licensed in the state where the patient is physically located at the time of the telehealth visit AND you comply with that state’s prescribing rules. For example, you could be based in California but treat a patient in Illinois as long as you hold active licenses in both states and follow Illinois’s regulations.

Q: How do I handle patients who move to a different state mid-treatment?
A: If a patient moves to a state where you’re not licensed, you cannot continue prescribing controlled substances to them via telehealth. You’ll need to either obtain a license in their new state or transition their care to a local provider. This is a common challenge in telehealth — many platforms (including Klarity) help manage these transitions.

Q: What’s the reimbursement landscape for telehealth narcolepsy care?
A: Most commercial insurers now cover telehealth at parity with in-person visits (thanks to COVID-era policy changes that many states made permanent). Medicare covers telehealth psychiatry broadly. However, reimbursement rates and prior authorization requirements vary by payer. Many telehealth providers also offer cash-pay options, which can be more straightforward administratively.

Sources and References

1. HHS Press Release – ‘HHS & DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026’ (Jan 2, 2026) www.hhs.gov

2. DEA Press Release – ‘DEA and HHS Extend Telemedicine Flexibilities through 2025’ (Nov 15, 2024) www.dea.gov

3. 21 U.S.C. §829(e) – Ryan Haight Act definitions (via Legal Information Institute, Cornell) www.law.cornell.edu

4. Nixon Peabody Law Alert – ‘New York State Finalizes Telemedicine Rule for Controlled Substances’ (June 18, 2025) www.nixonpeabody.com

5. Florida Statutes §456.47 – Use of Telehealth to Provide Services (2025 compilation) www.leg.state.fl.us

6. Florida Statutes §464.012 – APRN prescribing authority and formulary limits (2025) www.flsenate.gov

7. Texas Medical Board – APRN Prescriptive Delegation FAQs (2025) www.tmb.state.tx.us

8. California Board of Registered Nursing – Nurse Practitioner Schedule II Furnishing Requirements (2022) rn.ca.gov

9. Center for Connected Health Policy (CCHP) – ‘State Telehealth Laws and Reimbursement Policies Report’ (Fall 2025) www.cchpca.org

10. Pennsylvania Bulletin – Board of Nursing Regulatory Updates (2021-2022) www.pacodeandbulletin.gov

Source:

• https://www.law.cornell.edu/definitions/uscode.php?defid=21-USC-1796173870-113781527&height=800&iframe=true&termoccur=999&term_src=title%3A21%3Achapter%3A13%3Asubchapter%3AI%3Apart%3AC%3Asection%3A831&width=840#:~:text=,that%20a%20prescription%20has%20been
• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,while%20permanent%20rules%20are%20finalized
• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=promulgate%20a%20final%20set%20of,Medications%2C%E2%80%9D%20was%20submitted%20to%20the
• https://www.dea.gov/press-releases/2025/12/31/dea-extends-telemedicine-flexibilities-ensure-continued-access-care#:~:text=On%20January%2017%2C%202025%2C%20DEA,to%20as%20the%20%E2%80%9CTwo%20Final
• https://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499%2F0456%2FSections%2F0456.47.html#:~:text=telehealth%20to%20provide%20health%20care,in%20Schedule%20II%20of%20s
• https://www.tmb.state.tx.us/page/facility-based-prescriptive-delegation#:~:text=at%20the%20hospital%E2%80%99s%20facility,from%20a%20qualified%20hospice%20provider
• https://www.cchpca.org/resources/state-telehealth-laws-and-reimbursement-policies-report-fall-2025/#:~:text=Texas%20regulations%20emphasize%20continuity%20of,Note
• https://www.nixonpeabody.com/insights/alerts/2025/06/18/new-york-state-finalizes-telemedicine-rule-for-controlled-substances#:~:text=match%20at%20L114%20The%20rule,and%20the%20US%20Department%20of
• https://www.nixonpeabody.com/insights/alerts/2025/06/18/new-york-state-finalizes-telemedicine-rule-for-controlled-substances#:~:text=In%20short%2C%20the%20exception%20permits,as%20a%20condition%20of%20state
• https://rxagent.co/blog/np-prescribing-authority#:~:text=Conversely%2C%20in%20Restricted%20Practice%20states,expand%20this%20scope%20%206